Clinical Trial Update: Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan [Phase 4]

View source ↗

Summary

Phase 4 clinical trial pilot evaluating 18F-DCFPyL-PSMA PET imaging in men with metastatic castration-resistant prostate cancer who are receiving Lu-177 vipivot…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• 18F-DCFPyL-PSMA PET radiotracer (18F-DCFPyL PSMA PET radiotracer)
• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 4 | Status: RECRUITING